Guggenheim Capital LLC Cytokinetics Inc Transaction History
Guggenheim Capital LLC
- $12 Billion
- Q4 2024
A detailed history of Guggenheim Capital LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 35,988 shares of CYTK stock, worth $1.69 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
35,988
Previous 40,886
11.98%
Holding current value
$1.69 Million
Previous $2.16 Million
21.59%
% of portfolio
0.01%
Previous 0.02%
Shares
15 transactions
Others Institutions Holding CYTK
# of Institutions
396Shares Held
122MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$688 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$558 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$504 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.89MShares$370 Million0.07% of portfolio
-
State Street Corp Boston, MA6.17MShares$289 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.41B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...